BRPI0812170A8 - Moduladores de gama secretase - Google Patents

Moduladores de gama secretase

Info

Publication number
BRPI0812170A8
BRPI0812170A8 BRPI0812170A BRPI0812170A BRPI0812170A8 BR PI0812170 A8 BRPI0812170 A8 BR PI0812170A8 BR PI0812170 A BRPI0812170 A BR PI0812170A BR PI0812170 A BRPI0812170 A BR PI0812170A BR PI0812170 A8 BRPI0812170 A8 BR PI0812170A8
Authority
BR
Brazil
Prior art keywords
compounds
secretase
methods
modulators
formula
Prior art date
Application number
BRPI0812170A
Other languages
English (en)
Inventor
Zhu Zhaoning
J Greenlee William
Huang Xianhai
A Mckittrick Brian
W Clader John
D Mcbriar Mark
Palani Anandan
Original Assignee
Schering Corp
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Merck Sharp & Dohme filed Critical Schering Corp
Publication of BRPI0812170A2 publication Critical patent/BRPI0812170A2/pt
Publication of BRPI0812170A8 publication Critical patent/BRPI0812170A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

MODULADORES DE GAMA SECRETASE. Em suas muitas modalidades, a presente invenção fornece uma nova classe de compostos heterocíclicos da formula: Fórmula I como moduladores de gama secretase, métodos de preparação de tais compostos, composições farmacêuticas contendo um ou mais de tais compostos, métodos de preparação de formulações farmacêuticas compreendendo um ou mais de tais compostos, e métodos de tratamento, prevenção, inibição, ou melhora de uma ou mais doenças associadas com um sistema nervoso central usando tais compostos ou composições farmacêuticas não entram na inicial.
BRPI0812170A 2007-06-01 2008-05-28 Moduladores de gama secretase BRPI0812170A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94140507P 2007-06-01 2007-06-01
US98448407P 2007-11-01 2007-11-01
PCT/US2008/006734 WO2008153793A2 (en) 2007-06-01 2008-05-28 Gamma secretase modulators

Publications (2)

Publication Number Publication Date
BRPI0812170A2 BRPI0812170A2 (pt) 2014-12-02
BRPI0812170A8 true BRPI0812170A8 (pt) 2016-02-10

Family

ID=40084164

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812170A BRPI0812170A8 (pt) 2007-06-01 2008-05-28 Moduladores de gama secretase

Country Status (18)

Country Link
US (1) US8426403B2 (pt)
EP (1) EP2152695A2 (pt)
JP (1) JP5495331B2 (pt)
KR (1) KR20100037053A (pt)
CN (1) CN101809016A (pt)
AR (1) AR066152A1 (pt)
AU (1) AU2008263207B2 (pt)
BR (1) BRPI0812170A8 (pt)
CA (1) CA2689948A1 (pt)
CL (1) CL2008001560A1 (pt)
CO (1) CO6241123A2 (pt)
EC (1) ECSP099776A (pt)
IL (1) IL202315A0 (pt)
MX (1) MX2009013131A (pt)
PE (1) PE20090363A1 (pt)
RU (1) RU2009148866A (pt)
TW (1) TW200914459A (pt)
WO (1) WO2008153793A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2117311A4 (en) * 2007-02-08 2011-05-11 Merck Sharp & Dohme THERAPEUTICS
AU2009313538A1 (en) * 2008-11-06 2010-05-14 Merck Sharp & Dohme Corp. Gamma secretase modulators
CA2742472A1 (en) * 2008-11-13 2010-05-20 Schering Corporation Gamma secretase modulators
MX2011005046A (es) 2008-11-13 2011-06-01 Schering Corp Moduladores de gamma secretasa.
WO2010075204A2 (en) * 2008-12-22 2010-07-01 Schering Corporation Gamma secretase modulators
WO2010147975A1 (en) * 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
US20120238546A1 (en) * 2009-06-16 2012-09-20 Zhaoning Zhu Gamma secretase modulators
US20120232108A1 (en) * 2009-06-16 2012-09-13 Xianhai Huang Gamma secretase modulators
JP2014001142A (ja) * 2010-10-05 2014-01-09 Astellas Pharma Inc シクロアルカン化合物
JP5767393B2 (ja) 2011-03-31 2015-08-19 ファイザー・インク 新規二環式ピリジノン
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
US9598437B2 (en) 2013-12-04 2017-03-21 Merck Sharp & Dohme Corp. Gamma secretase modulators
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
DK3253755T3 (da) 2015-02-03 2020-09-28 Pfizer Hidtil ukendte cyclopropabenzofuranyl-pyridopyrazindioner
US20230137562A1 (en) 2017-06-07 2023-05-04 Adrx, Inc. Tau aggregation inhibitors
CA3073062A1 (en) 2017-08-18 2019-02-21 Adrx, Inc. Tau aggregation peptide inhibitors
EP3760619B1 (en) 2018-02-28 2023-10-25 Japan Tobacco Inc. Saturated ring-condensed dihydropyrimidinone or dihydrotriazinone compound, and pharmaceutical use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1065324A (en) 1974-05-13 1979-10-30 E.R. Squibb And Sons 2-aminoalkyl-3,3a,4,5,6,7-hexahydro-3-phenyl-7-(phenylmethylene)-2h-indazoles and related cyclohepta (c) pyrazoles and cyclopentapyrazoles
CH594667A5 (en) 1974-05-31 1978-01-13 Squibb & Sons Inc Hexahydro-2H-pyrazolo(4,3-C) pyridine derivs
US3979381A (en) 1975-08-11 1976-09-07 E. R. Squibb & Sons, Inc. Thiopyrano[4,3-c] pyrazoles
US4003890A (en) * 1976-05-27 1977-01-18 E. R. Squibb & Sons, Inc. Benzylidene pyrano[4,3-c]pyrazoles
US4065617A (en) * 1977-02-04 1977-12-27 E. R. Squibb & Sons, Inc. 2-(2,2,2,-Trifluoroethyl)-3,3a,4,5,6,7-hexahydro-2H-pyrazolo[4,3-c]pyridines
AU757290B2 (en) * 1998-03-25 2003-02-13 Bristol-Myers Squibb Company Imidazolone anorectic agents: II. phenyl derivatives
ES2220753T3 (es) * 2000-03-20 2004-12-16 N-Gene Research Laboratories Inc. Derivados de amidoxina del acido propencarboxilico, procedimiento para su preparacion, y composiciones farmaceuticas que los contienen.
EP1603548A4 (en) 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
JP4847868B2 (ja) 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
WO2006001877A2 (en) 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
JP2007538024A (ja) 2004-05-19 2007-12-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アミロイドベータペプチドのレベル変化に関連する疾患及び状態の治療方法及び新規エノールカルボキサミド化合物
MXPA06013534A (es) * 2004-05-26 2007-05-10 Eisai R&D Man Co Ltd Compuesto de cinamida.
EP1650183A1 (en) 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy
TWI370130B (en) * 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
BRPI0618814A2 (pt) * 2005-11-24 2014-04-29 Eisai R&D Man Co Ltd Composto ou um sal farmacologicamente aceitável do mesmo, e, agente farmacêutico
KR101464651B1 (ko) * 2006-03-09 2014-11-24 에자이 알앤드디 매니지먼트 가부시키가이샤 다환식 신나미드 유도체
KR20100017573A (ko) 2007-05-07 2010-02-16 쉐링 코포레이션 감마 세크레타제 조정인자
KR20100021633A (ko) 2007-06-01 2010-02-25 쉐링 코포레이션 감마 세크레타제 조절인자
MX2011005046A (es) 2008-11-13 2011-06-01 Schering Corp Moduladores de gamma secretasa.

Also Published As

Publication number Publication date
CA2689948A1 (en) 2008-12-18
KR20100037053A (ko) 2010-04-08
RU2009148866A (ru) 2011-07-20
US8426403B2 (en) 2013-04-23
US20100256128A1 (en) 2010-10-07
CN101809016A (zh) 2010-08-18
EP2152695A2 (en) 2010-02-17
WO2008153793A2 (en) 2008-12-18
AU2008263207A1 (en) 2008-12-18
CO6241123A2 (es) 2011-01-20
MX2009013131A (es) 2010-01-15
JP5495331B2 (ja) 2014-05-21
AU2008263207A2 (en) 2010-01-28
ECSP099776A (es) 2010-01-29
BRPI0812170A2 (pt) 2014-12-02
TW200914459A (en) 2009-04-01
JP2010529015A (ja) 2010-08-26
WO2008153793A3 (en) 2009-03-19
AU2008263207B2 (en) 2013-10-03
CL2008001560A1 (es) 2009-05-22
AR066152A1 (es) 2009-07-29
PE20090363A1 (es) 2009-04-01
IL202315A0 (en) 2010-06-30

Similar Documents

Publication Publication Date Title
BRPI0812170A8 (pt) Moduladores de gama secretase
MX2009012177A (es) Moduladores de gamma-secretasa.
PH12020550450A1 (en) Certain chemical entities, compositions and methods
BRPI0616987A2 (pt) pirazolopirimidinas como inibidores de cinase dependente de ciclina
BRPI0507644A (pt) pirazolopirimidinas como inibidores de cinase dependente de ciclina
MY162604A (en) Heterocyclic compounds and uses thereof
BR112012004453A8 (pt) composto inibidor de proteína quinase, sua composição farmacêutica e seu uso
MY172151A (en) Certain chemical entities, compositions and methods
ATE482209T1 (de) Verbindungen und zusammensetzungen als modulatoren der gpr119-aktivität
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
BRPI0508820B8 (pt) compostos moduladores de receptor de opióide e composição que os compreende
TW200615266A (en) Organic compounds
BR112012007747A2 (pt) Compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos
MX2010003397A (es) Moduladores de la gamma secretasa.
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BR112014004465A2 (pt) compostos e composições como inibidores de pdgfr cinase
BRPI0410913A (pt) benzotiofenos substituìdos com cicloalquil e heterocicloalquil como agentes terapêuticos
BR112012028445A2 (pt) compostos de heteroarila bicíclica como moduladores de gpr119
BR112013032391A2 (pt) antagonistas de trpv4
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
UY30363A1 (es) Derivados sustituidos de la n-(3-oxo-2,3-dihidro-1h-isoindol-4-il)-1-naftamida, procesos de preparacion, composiciones farmacéuticas y aplicaciones
MX2009013130A (es) Moduladores de gamma secretasa.
BR112015006727A8 (pt) uso de uma composição farmacêutica
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.